Disclosure. Malo Clinic is not a commercial partner of this publication. SmileJet and Picasso Dental Clinic are affiliated with this publication; neither operates in Portugal, and neither has any relationship with Malo Clinic or any connected entity. This review was produced without payment, accommodation, travel, equipment, or any other consideration from Malo Clinic. The publication’s standing disclosures are at /disclosures/.
Why this review exists — the first Portuguese clinic, the most published founder in this series
This is the first Portuguese clinic this publication has reviewed. It is also the review in which I have had to think hardest about how to separate founder credentials from clinic-level transparency obligations, because in this case the two questions pull in different directions.
Dr. Paulo Malo’s name appears on foundational papers in implant dentistry. The All-on-4 treatment concept — tilted posterior implants supporting a full-arch fixed restoration, enabling immediate loading without bone grafting in many cases — is documented in PubMed literature from the early 2000s with Malo Clinic stated as the institutional affiliation. By 2025, hundreds of thousands of All-on-4 procedures have been performed globally by practitioners who learned the technique from those publications. Nobel Biocare publicly recognised Dr. Malo in 2023 for 25 years of the concept. That is not a marketing claim — it is a matter of published record.
The framework I use, however, asks five specific questions. The answers to those questions — not my general view of Dr. Malo’s contribution to implant dentistry — are what determine the rating. Two categories produce PASS findings. Three produce CONCERN findings. The CONCERN finding stands.
This review applies the clinical-standards framework on the credential-verifiability and evidence-quality axes.
Corporate structure
MALO CLINIC, S.A. is a Portuguese company. Its Portuguese incorporation number is 503411434. The clinic’s principal address is Av. dos Combatentes 43A, Lisbon. Founded in 1995, the clinic predates the first published All-on-4 clinical series by approximately eight years. It is the institution in which the All-on-4 concept was developed and initially tested.
A UK overseas entity — FC030795 — was registered at Elmfield House, High Street, Teddington TW11 8EW from 1 January 2012. That entity is now listed at Companies House as Converted/Closed, with a closure date of 25 October 2013. The UK entity existed for less than two years. It is not noted here as a clinical risk. It is noted because any UK patient who has encountered references to a UK presence, or who assumed a UK-registered entity still exists, should be aware that there is no active UK Companies House entity for Malo Clinic.
The Portuguese NIPC (Número de Identificação de Pessoa Coletiva — the Portuguese tax identification number for legal entities) is not publicly accessible from primary sources reviewed for this piece. The incorporation number 503411434 is stated in the public record.
For UK patients: the legal counterparty for any treatment contract is a Portuguese company, under Portuguese law, in Portuguese courts. Post-Brexit, EU Directive 2011/24/EU no longer confers cross-border rights to UK patients. For Australian and New Zealand patients, Directive coverage was never applicable; all costs are private regardless.
Dr. Paulo Malo — credentials and PubMed record
Dr. Paulo Malo graduated from the Faculty of Dental Medicine (Faculdade de Medicina Dentária) at the University of Lisbon in 1989. His title is Prosthodontist and Oral Surgeon. His degree institution — the University of Lisbon Faculty of Dental Medicine — is the first Portuguese university to have taught Dental Medicine and is ranked number one in Portugal across multiple international academic ranking systems including Shanghai-ARWU, QS, Scimago, and NTU. The degree itself is EU-recognised.
The All-on-4 concept was developed by Dr. Malo in the early 1990s in collaboration with Dr. Bo Rangert of Nobel Biocare. The first patient was treated in 1998. The foundational published clinical series followed from 2003 onwards.
His verifiable PubMed publication record includes, at minimum:
- Malo P et al. (2000): Immediate implant function in esthetic zones — an early paper establishing the institutional research trajectory.
- Malo P et al. (2003): First prospective study of the All-on-4 concept for mandibular rehabilitation — this is the foundational clinical paper that defined the technique’s evidence base.
- Malo P, de Araújo Nobre M, et al. (2012): “All-on-4 immediate-function concept for completely edentulous maxillae: a clinical report on the medium (3 years) and long-term (5 years) outcomes,” published in Clinical Implant Dentistry and Related Research.
- Malo P et al. (2019): Five-to-thirteen-year outcomes of All-on-4 for edentulous maxilla rehabilitation.
The 2003 and 2012 papers in particular are cited in subsequent systematic reviews, including the Soto-Penaloza 2017 review discussed in detail below. The institutional affiliation — Malo Clinic — is stated in those publications. This is the most extensive PubMed record for any founder in this European review series by a material margin.
The OMD qualification. The Ordem dos Médicos Dentistas (OMD) is the mandatory professional regulatory body for all practising Portuguese dentists. Its public register is searchable at omd.pt. Dr. Malo’s OMD registration number is not published in any publicly accessible clinic material reviewed for this piece. The register exists and is searchable — patients can use it directly — but the clinic’s decision not to publish the registration number means a patient must run the search independently rather than verifying a stated number. That is a transparency gap, not a regulatory failing: the OMD system is functional and the answer is available to any patient willing to look it up.
The All-on-4 evidence base — where the intellectual weight of this review sits
This section is longer than the equivalent section in any other clinic review in this series, because this is where the evidence questions are most consequential and most complicated.
What the technique is
All-on-4 is a full-arch immediate-function implant protocol: four implants per arch (two axial anteriors, two posteriorly tilted at up to 45 degrees) supporting a fixed prosthetic bridge, often loaded within 24 to 72 hours of surgery. The posterior tilt is designed to avoid the inferior alveolar nerve and maximise available anterior bone, reducing or eliminating the need for sinus augmentation or bone grafting in many patients. For edentulous patients or those requiring full-arch extraction, it is faster, cheaper, and often surgically less invasive than conventional six-to-eight-implant full-arch protocols.
The technique was published, refined, and reported predominantly by the team that invented it. That is the central complication in assessing the evidence base.
The Soto-Penaloza systematic review (2017)
The most accessible systematic review of All-on-4 outcomes is Soto-Penaloza et al. (2017), conducted at the University of Valencia and published in the Journal of Clinical and Experimental Dentistry (PMID 28298995; PMC5347302). The methodology: 728 papers screened, 24 met inclusion criteria covering January 2005 to April 2016.
The headline finding — an implant survival rate above 99.8% at greater than 24 months follow-up — is the number that appears in clinic marketing worldwide, including contexts entirely disconnected from Malo Clinic itself.
The finding that appears less often in clinic marketing is this: 12 of 13 included studies had high risk of bias.
That is not a peripheral observation. It is a statement about the quality of the evidence base from which the 99.8% figure is drawn. The Soto-Penaloza authors are explicit about it: most All-on-4 evidence is retrospective, conducted at the originating clinic, reported by the treating practitioners, and not independently verified. There are no adequately powered randomised controlled trials comparing All-on-4 to conventional full-arch implant protocols. The survival rate data comes predominantly from non-independent, clinic-reported cohorts — of which Malo Clinic’s own published series forms a significant proportion.
I am not suggesting the reported outcomes are fabricated. I am stating what the evidence structure is: high-volume, long-term, clinic-reported data from the institution that invented and commercially promotes the technique, assessed by a systematic review that found most included studies at high risk of bias. A patient considering All-on-4 should understand that distinction before they travel.
The Browaeys critique (University of Ghent, 2015)
The most challenging independent finding in the All-on-4 literature comes from Browaeys et al. (2015), conducted at the University of Ghent Faculty of Medicine and Health Sciences and published in Clinical Implant Dentistry and Related Research (doi: 10.1111/cid.12197).
The study examined 80 implants in patients treated under the All-on-4 protocol using computer-guided flapless surgery with immediate loading. The finding: 49.2% of implants showed unacceptable ongoing bone loss at three years.
That is not a survival failure in the conventional sense — the implants were still osseointegrated. Unacceptable ongoing bone loss (crestal bone loss beyond the threshold defined as clinically acceptable in the literature) is a precursor finding that can precede late implant failure, prosthetic complications, and aesthetic deterioration. The 49.2% figure is from one cohort, using one surgical variant (flapless, computer-guided), and should not be extrapolated as an absolute rate for All-on-4 globally. But it is an independent finding from a university research group with no commercial relationship to the technique’s development, and it directly contradicts the impression created by a 99.8% survival headline.
The honest framing is this: All-on-4 has a large body of published clinical data. That body of data is heavily weighted toward the institution that invented and commercialised the technique. The independent evidence is thinner and, where it exists, raises questions about bone-loss outcomes that clinic-reported survival data does not surface. A patient booking this procedure should ask their treating clinician about bone-loss monitoring protocols, specifically crestal bone resorption measurements at 12 and 36 months.
Malo Clinic’s own reported outcomes
For completeness: Malo Clinic’s own published data reports approximately 94.7% implant cumulative survival, 93.9% success rate, and 99.2% prosthetic success at up to 13 years. These are clinic-reported numbers. The 13-year follow-up period is longer than most independent data in the literature. The source is the same institution that developed, practices, and trains clinicians in the technique. That context does not make the numbers wrong; it is the context in which any patient should understand them.
What this means for a patient
The All-on-4 evidence situation is more complicated than almost any other procedure reviewed in this series. There is more published data than for any technique a patient will encounter in dental tourism. Most of it comes from one institution. The independent data is limited, the best systematic review identifies high bias risk in its included studies, and the one well-designed independent cohort study found a bone-loss outcome that would give most clinicians pause.
A patient who is a good candidate for All-on-4 — edentulous or requiring full-arch extraction, adequate anterior bone volume, no significant contraindications — may well receive excellent outcomes here or at any experienced clinic practising the technique. A patient who is selecting a clinic on the basis that “the evidence says it works” needs to understand what that evidence actually shows.
The Portuguese regulatory framework
Ordem dos Médicos Dentistas (OMD). All practising Portuguese dentists must be OMD members. OMD membership is a legal precondition of practice in Portugal — equivalent in mandatory-registration architecture to the Croatian HKDM, the Czech ČSK, and the Polish NIL. The OMD’s public register at omd.pt/en/search-for-dentists/ is searchable by patients, including patients outside Portugal. This is one of the stronger patient-verification tools in Europe: you can search for a named dentist, confirm their registration status, and identify their specialty designation before travelling.
The meaningful gap specific to Malo Clinic is that the clinic does not publish OMD registration numbers for its clinical team in any publicly accessible source reviewed here. The register’s existence is a transparency positive for Portugal as a dental tourism environment. The absence of a published OMD number for Dr. Malo or any named clinician is a gap the clinic could close by simply publishing the number — it is a gap the patient can close by searching omd.pt directly.
University of Lisbon Faculty of Dental Medicine. The FMD is ranked number one in Portugal by multiple international academic ranking systems (Shanghai-ARWU, QS, Scimago, NTU). It is the first Portuguese university to have taught Dental Medicine. Degrees from FMD are EU-recognised under the Professional Qualifications Directive. A graduating dentist from FMD holds a qualification that is mutually recognised across EU member states. This is the same qualification pathway as Charles University Prague and the University of Zagreb, and it is a materially higher regulatory floor than the Turkish qualification landscape reviewed earlier in this series.
EU Directive 2011/24/EU. Portugal is an EU member state and has implemented the Directive. For EU-citizen patients — German, French, Irish, Dutch, Austrian — the Directive creates a cross-border healthcare rights framework. The relevant limitations for international dental tourism patients are: the Directive’s reimbursement provisions do not cover elective dental procedures that are not included in the home-country statutory health basket, which excludes implants, full-arch restorations, and most cosmetic dentistry for most EU source markets. The Directive is more useful as a patient-rights accountability framework than as a reimbursement mechanism for the high-cost elective procedures most dental tourists seek.
UK patients post-Brexit. From 1 January 2021, UK patients are outside Directive 2011/24/EU. There is no UK-Portugal bilateral healthcare agreement replacing it. A UK patient who experiences a complication after returning home has no Directive-based recourse route; their position is a private contractual claim against a Portuguese company, under Portuguese law, in Portuguese courts. With no active UK entity at Companies House, there is no UK-jurisdiction counterparty.
Scoring
Category 1 — Clinical governance and registration.
Category 2 — Procedure-specific competence evidence.
Category 3 — Infection control and sterilisation standards.
Category 4 — Continuity of care for international patients.
Category 5 — Transparency of corporate and ownership structure.
What would change this assessment
The CONCERN finding is not a finding about Dr. Malo’s clinical ability. It is a finding about three specific gaps. Each is addressable.
First: publish OMD registration numbers for Dr. Malo and the named clinical team. The OMD register is publicly searchable; the clinic can close this gap by stating the registration number alongside each clinician’s name in its publicly accessible materials. This is a minor transparency step with material impact for international patients.
Second: independent outcome auditing. The All-on-4 evidence base would be materially strengthened by any independent verification of Malo Clinic’s reported outcomes — an independent cohort study with external authorship, an audit by an independent academic institution, or a prospective registry with named independent oversight. The clinic-reported numbers may be accurate. Their evidential weight would be higher if confirmed by a source with no financial relationship to the technique’s commercialisation.
Third: a documented international-patient continuity protocol with named post-treatment contacts, defined response times, and written warranty terms available before booking. The clinic’s reputation and the volume of international patients it treats suggest this infrastructure likely exists in practice; making it publicly available in writing before treatment is a transparency commitment that the current public record does not show.
Fourth: independent accreditation confirmation. If JCI or equivalent accreditation is held, publishing the certification body, programme, and certification number would move Category 3 from CONCERN toward PASS.
Questions a patient should ask before booking
Submit these in writing and expect written answers before any deposit is paid or travel arranged.
- What is Dr. Malo’s (or the assigned treating clinician’s) OMD registration number, and what specialty designation does the OMD register record for them?
- What independent third-party verification exists for the clinic’s reported 13-year All-on-4 outcome data — specifically, what organisation or institution has audited or co-authored those outcomes independently of Malo Clinic staff?
- What is the clinic’s crestal bone-loss monitoring protocol after All-on-4 placement — specifically, at what intervals are radiographic measurements taken, and what threshold triggers a clinical review?
- What is the written protocol for an international patient who returns home and develops a complication — who is the named clinical contact, what is the response time commitment, and what revision work falls within the warranty?
- Does the clinic hold JCI accreditation or any equivalent independently audited accreditation? If so, which programme and what is the certification number?
- What is the post-treatment flight protocol following sinus augmentation or full-arch implant placement?
Overall finding
CONCERN — strongest PubMed record in this European series; All-on-4 evidence base carries documented bias risk; no active UK entity; OMD number not published.
Malo Clinic occupies an unusual position in this review series. The founder’s clinical publication record is, by a material margin, the most extensive of any clinic reviewed here. Dr. Paulo Malo did not merely claim expertise in a technique; he invented it, published the foundational clinical series, collaborated with the leading implant company in the space, and built a body of work over more than two decades that is cited in the literature the rest of the field uses. That is a different order of clinical credential from what any other European dental tourism clinic reviewed here can offer.
The CONCERN finding does not dispute any of that. The framework asks five specific questions, and three of them — infection control and sterilisation verification, international continuity of care, and corporate transparency — produce CONCERN findings that the PubMed record does not resolve.
On the evidence question: the All-on-4 technique is probably more rigorously documented than any other procedure marketed in dental tourism. It is also documented in ways that make critical reading essential rather than optional. A 99.8% survival rate from a systematic review in which 12 of 13 studies were assessed as high risk of bias is not the same as a 99.8% survival rate from independent RCT data. The Browaeys finding — 49.2% unacceptable bone loss at three years in one independent cohort — is not explained away by the volume of clinic-reported data that preceded it. A patient deciding whether to have All-on-4 anywhere, not just at Malo Clinic, should understand both findings.
Portugal’s OMD register is the strongest mandatory-registration patient-verification tool reviewed in this Western European series. The clinic’s decision not to publish its OMD registration number means patients must use that tool unprompted rather than verifying a stated number — a small but real transparency gap in a context where transparency steps matter.
Re-review cadence: 12 months, or earlier on submission of: (1) published OMD registration numbers for named clinicians; (2) independent accreditation confirmation if held; (3) written international-patient continuity protocol available pre-booking; and (4) any independent audit or external co-authorship of the clinic’s long-term outcome data.
See also
- All-on-4 patient guide — procedure-specific framework for patients evaluating full-arch implant options
- The dental tourism trust gap — the structural information asymmetry problem this review sits within
- Clinical standards framework — the five-category methodology applied here
- When to go overseas for dental treatment — and when not to — the four-filter patient-side decision framework
- Dentum, Zagreb — clinical review — EU dental tourism in Croatia; anonymous team structure in an EU regulatory environment
- Smile Centrum, Prague — clinical review — EU dental tourism in the Czech Republic; ČSK mandatory registration and the anonymous-team transparency problem
Sources
- Companies House — Malo Clinic S.A. (FC030795): https://find-and-update.company-information.service.gov.uk/company/FC030795
- Wikipedia — Paulo Maló: https://en.wikipedia.org/wiki/Paulo_Mal%C3%B3
- OMD public register — Ordem dos Médicos Dentistas: https://www.omd.pt/en/search-for-dentists/
- PubMed — Soto-Penaloza et al. 2017 (PMID 28298995): https://pubmed.ncbi.nlm.nih.gov/28298995/
- PMC — Soto-Penaloza et al. 2017 full text (PMC5347302): https://pmc.ncbi.nlm.nih.gov/articles/PMC5347302/
- Browaeys et al. 2015 — Ongoing crestal bone loss, All-on-4 (doi:10.1111/cid.12197): https://doi.org/10.1111/cid.12197
- EU Directive 2011/24/EU on Cross-Border Healthcare (EUR-Lex): https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2011:088:0045:0065:EN:PDF
- Wikipedia — Faculty of Dental Medicine, University of Lisbon: https://en.wikipedia.org/wiki/Faculty_of_Dental_Medicine,_University_of_Lisbon
- Wikipedia — Nobel Biocare: https://en.wikipedia.org/wiki/Nobel_Biocare